LADENBURG THALM/SH SH Raises TG Therapeutics (NASDAQ:TGTX) Price Target to $40.00

TG Therapeutics (NASDAQ:TGTX) had its price target hoisted by LADENBURG THALM/SH SH from $39.00 to $40.00 in a research note released on Thursday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on TGTX. The Goldman Sachs Group upped their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a neutral rating in a research note on Thursday, February 29th. B. Riley raised their price target on TG Therapeutics from $24.00 to $29.00 and gave the stock a buy rating in a research note on Monday, February 5th. HC Wainwright restated a buy rating and set a $45.00 price target on shares of TG Therapeutics in a report on Thursday, April 18th. JPMorgan Chase & Co. reaffirmed an overweight rating and issued a $25.00 price target on shares of TG Therapeutics in a research report on Thursday, April 18th. Finally, StockNews.com lowered TG Therapeutics from a buy rating to a hold rating in a report on Saturday, February 24th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $29.83.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX traded down $0.23 during mid-day trading on Thursday, reaching $16.19. The company had a trading volume of 4,804,428 shares, compared to its average volume of 3,980,529. The company has a 50-day moving average price of $15.25 and a two-hundred day moving average price of $14.41. The stock has a market cap of $2.50 billion, a PE ratio of 70.39 and a beta of 2.33. The company has a current ratio of 5.92, a quick ratio of 5.18 and a debt-to-equity ratio of 0.62. TG Therapeutics has a 1-year low of $6.46 and a 1-year high of $35.67.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). TG Therapeutics had a return on equity of 33.79% and a net margin of 14.24%. The firm had revenue of $63.47 million during the quarter, compared to analyst estimates of $54.60 million. During the same period in the prior year, the business posted ($0.28) EPS. The company’s revenue for the quarter was up 713.5% on a year-over-year basis. On average, equities analysts anticipate that TG Therapeutics will post -0.08 earnings per share for the current year.

Insider Buying and Selling at TG Therapeutics

In other news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the completion of the transaction, the director now directly owns 215,229 shares of the company’s stock, valued at approximately $3,437,207.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Hedge funds have recently modified their holdings of the stock. 683 Capital Management LLC acquired a new stake in shares of TG Therapeutics in the 3rd quarter valued at $11,286,000. Norges Bank acquired a new stake in TG Therapeutics during the 4th quarter valued at $18,362,000. Schonfeld Strategic Advisors LLC raised its position in TG Therapeutics by 164.5% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 1,367,400 shares of the biopharmaceutical company’s stock valued at $11,431,000 after purchasing an additional 850,507 shares during the last quarter. Rafferty Asset Management LLC grew its holdings in shares of TG Therapeutics by 183.2% during the third quarter. Rafferty Asset Management LLC now owns 856,837 shares of the biopharmaceutical company’s stock worth $7,163,000 after purchasing an additional 554,309 shares during the last quarter. Finally, Eventide Asset Management LLC bought a new position in shares of TG Therapeutics in the fourth quarter valued at about $7,506,000. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.